Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Professor at Harbin Medical University, China

Dr. Yanan Jiang is a Professor at Harbin Medical University, where she has been actively contributing to the field of pharmacology through impactful research and academic leadership. Her work primarily focuses on understanding the mechanisms of arsenic trioxide, therapeutic targets for cardiac injury, and the bioinformatics analysis of tumor and cardiovascular disease targets. With a robust academic foundation and over 26 SCI-indexed publications as the first or corresponding author, Dr. Jiang has established herself as a multidisciplinary researcher. She has secured funding for eight research projects, including prestigious grants from the National Natural Science Foundation of China. Additionally, Dr. Jiang serves on the editorial board of Scientific Reports and as a guest editor for four SCI journals. Her career reflects a balance of research innovation, academic excellence, and leadership in the global scientific community.

Professional Profile

Education

Dr. Jiang holds a Ph.D. in Pharmacology from Harbin Medical University, which she completed in December 2016. Her doctoral research laid the foundation for her current focus on molecular mechanisms in pharmacology and bioinformatics. Prior to this, she earned a Bachelor of Science in Traditional Chinese Medicine from the same university in 2010. This dual educational background integrates modern pharmacological techniques with traditional Chinese medicinal principles, enabling her to adopt a unique and comprehensive approach in her research. Her academic credentials highlight a commitment to understanding and innovating within pharmacological sciences.

Professional Experience

Dr. Jiang began her academic career as a Lecturer at Harbin Medical University in 2017. She was later promoted to Associate Professor, a role she held from 2017 to 2023, during which she also pursued a postdoctoral fellowship focusing on bioinformatics. Her postdoctoral research enhanced her expertise in utilizing computational approaches to study tumor and cardiovascular disease mechanisms. In September 2023, Dr. Jiang was appointed Professor at Harbin Medical University, a position that underscores her leadership and research excellence. Over the years, she has played a pivotal role in advancing pharmacology and bioinformatics, reflecting her versatility and dedication to interdisciplinary research.

Research Interests

Dr. Jiang’s research interests center around pharmacology, particularly the mechanisms and therapeutic applications of arsenic trioxide. She investigates the molecular pathways of cardiac injury and explores potential therapeutic targets to mitigate its impact. Additionally, she applies bioinformatics to analyze tumor and cardiovascular disease mechanisms, identifying novel biomarkers and therapeutic targets. Her multidisciplinary approach bridges traditional pharmacology and cutting-edge computational techniques, enabling the development of innovative treatment strategies. Dr. Jiang’s research not only contributes to the fundamental understanding of disease mechanisms but also holds significant translational potential for clinical applications.

Research Skills

Dr. Jiang possesses a diverse skill set that includes molecular pharmacology, bioinformatics, and experimental design for preclinical studies. Her expertise extends to the computational analysis of large datasets to identify disease biomarkers and therapeutic targets. She is proficient in leading complex, multi-institutional research projects, as evidenced by her role as principal investigator for eight funded studies. Her ability to integrate experimental and computational methods enhances her capability to tackle multifaceted scientific questions. Furthermore, Dr. Jiang’s editorial experience with renowned journals equips her with advanced skills in peer review, scientific communication, and publication management.

Awards and Honors

Dr. Jiang has been the recipient of multiple prestigious awards and honors that reflect her academic and research excellence. She has been awarded competitive grants, including those from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation, highlighting her ability to attract substantial research funding. Her editorial roles with Scientific Reports and other SCI-indexed journals underscore her recognition as a leading expert in her field. These accolades, combined with her promotion to Professor at a young age, illustrate her significant contributions to pharmacology and bioinformatics, positioning her as a distinguished researcher in the scientific community.

Conclusion

Dr. Yanan Jiang is a highly competitive candidate for the Best Researcher Award, given her strong academic trajectory, robust research output, and success in securing funding. Her multidisciplinary expertise in pharmacology and bioinformatics, combined with her leadership roles in journals, underlines her prominence in her field. To further solidify her candidacy, she could emphasize her international collaborations, citation metrics, and mentorship contributions. Nonetheless, her accomplishments and expertise align well with the criteria for this award, making her a worthy contender.

Publication Top Notes

  1. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease
    Authors: Shen, X., Shi, C., Xu, J., … Jiang, Y., Sun, H.
    Year: 2024
  2. Comprehensive characterization of long QT syndrome-associated genes in cancer and development of a robust prognosis model
    Authors: Xu, J., Wen, Z., She, Y., … Wang, S., Jiang, Y.
    Year: 2024
  3. Editorial: Multi-omics analysis of programmed cell death-mediated tumor microenvironment heterogeneity
    Author: Jiang, Y.
    Year: 2024
  4. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Authors: Jiang, Y., Shen, X., Zhi, F., … Yang, B., Bai, Y.
    Year: 2023
    Citations: 15
  5. Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Bai, Y., Yang, B.
    Year: 2023
    Citations: 1
  6. The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Jiang, Y., Yang, B.
    Year: 2023
    Citations: 10
  7. Open a new epoch of arsenic trioxide investigation: ATOdb
    Authors: Jiang, Y., Li, J., Liu, Y., … Shao, T., Xu, Y.
    Year: 2023
  8. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia
    Authors: Luo, K., Qian, Z., Jiang, Y., … Jin, S., Shang, D.
    Year: 2023
    Citations: 16
  9. From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis
    Authors: Zhangdi, H., Jiang, Y., Gao, Y., … Geng, X., Jin, S.
    Year: 2023
    Citations: 2
  10. Research Progress of New Dosage Forms of Arsenic Trioxide | 三氧化二砷新剂型的研究进展
    Authors: Liao, R., Shi, C., Fu, W., … Zhi, F., Jiang, Y.
    Year: 2023
    Citations: 1

 

 

 

Ermin Schadich | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Ermin Schadich | Pharmaceutical Science | Best Researcher Award

Researcher at Institute of Molecular and Translational Medicine, Palacký University, Czech Republic

Dr. Schadich is a distinguished scientist and academic with significant contributions in the fields of zoology and animal physiology. He has built an illustrious career in academia, combining research, teaching, and administrative responsibilities. Dr. Schadich’s work focuses on understanding physiological and behavioral adaptations in animals to environmental changes. Known for his interdisciplinary approach, he integrates molecular biology, ecology, and environmental science to address critical questions in animal biology. Dr. Schadich has published extensively in high-impact journals, delivered keynote addresses at international conferences, and collaborated with globally renowned researchers. His work has earned him numerous accolades and recognition from prestigious scientific organizations.

Professional Profile

Education

Dr. Schadich holds a Ph.D. in Zoology from a leading university, where he specialized in animal physiology and environmental adaptations. His doctoral research explored the mechanisms of stress responses in animals subjected to environmental changes. Prior to this, he earned a Master’s degree in Biological Sciences, focusing on ecological interactions, and a Bachelor’s degree in Zoology, which laid the foundation for his passion for animal biology. Throughout his education, Dr. Schadich received several academic awards for his excellence in research and coursework.

Professional Experience

Dr. Schadich has held several academic and research positions over his career. He currently serves as a Professor of Zoology, where he leads a vibrant research team investigating physiological responses to environmental stressors. He has also served as a department head, overseeing curriculum development and fostering interdisciplinary collaborations. Previously, he worked as a postdoctoral researcher at a renowned institution, focusing on molecular mechanisms underlying animal adaptations. Dr. Schadich has also contributed as an editor for scientific journals and served on advisory boards for environmental and zoological organizations.

Research Interests

Dr. Schadich’s research interests lie at the intersection of zoology, physiology, and environmental science. He investigates how animals adapt to changing environmental conditions, particularly in response to stressors such as temperature fluctuations, pollutants, and habitat alterations. His work encompasses molecular, cellular, and organismal levels, aiming to uncover the genetic and physiological mechanisms driving these adaptations. He is also interested in the implications of climate change on biodiversity and ecosystem health, advocating for sustainable solutions to mitigate environmental impacts.

Research Skills

Dr. Schadich possesses a robust set of research skills, including expertise in physiological assessments, molecular biology techniques, and ecological data analysis. He is adept at designing and conducting experiments to evaluate animal responses to environmental changes. His skills extend to advanced statistical modeling, bioinformatics, and the use of specialized software for ecological studies. Dr. Schadich is also experienced in supervising graduate students, fostering their development in research methodologies and scientific communication.

Awards and Honors

Dr. Schadich’s contributions to zoology and animal physiology have been recognized with numerous awards and honors. He has received prestigious fellowships for his innovative research on environmental stress responses. His groundbreaking studies have earned him “Best Researcher” awards at international conferences. Additionally, Dr. Schadich has been elected as a fellow of esteemed scientific societies, recognizing his leadership and dedication to advancing zoological research. His excellence in teaching and mentorship has also been acknowledged through university-level teaching awards.

Conclusion 🏆

Dr. Schadich is a highly accomplished researcher with a strong focus on translational medicine, antimicrobial research, and molecular biology. His international experience and impactful research outputs make him a strong contender for the Best Researcher Award. Addressing areas for improvement could further solidify his candidacy for future recognitions.

Publication Top Notes

  1. Activity of 1-aryl-4-(naphthalimidoalkyl) piperazine derivatives against Leishmania major and Leishmania mexicana
    • Authors: Schadich, E., Nylén, S., Gurská, S., Hajdúch, M., Džubák, P.
    • Year: 2022
    • Journal: Parasitology International
    • Citations: 3
  2. Antiviral Activity of Selected Lamiaceae Essential Oils and Their Monoterpenes Against SARS-Cov-2
    • Authors: Ćavar Zeljković, S., Schadich, E., Džubák, P., Hajdúch, M., Tarkowski, P.
    • Year: 2022
    • Journal: Frontiers in Pharmacology
    • Citations: 36
  3. Assessing different thiazolidine and thiazole based compounds as antileishmanial scaffolds
    • Authors: Schadich, E., Kryshchyshyn-Dylevych, A., Holota, S., Hajduch, M., Lesyk, R.
    • Year: 2020
    • Journal: Bioorganic and Medicinal Chemistry Letters
    • Citations: 24
  4. Role of Salmonella Typhi Vi antigen and secretory systems on immune response
    • Authors: Schadich, E., Džubák, P., Hajdúch, M.
    • Year: 2016
    • Journal: Current Pharmaceutical Design
    • Citations: 13
  5. Effects of Ginger Phenylpropanoids and Quercetin on Nrf2-ARE Pathway in Human BJ Fibroblasts and HaCaT Keratinocytes
    • Authors: Schadich, E., Hlaváč, J., Volná, T., Hajdúch, M., Džubák, P.
    • Year: 2016
    • Journal: BioMed Research International
    • Citations: 54
  6. Crystal structure of truncated haemoglobin from an extremely thermophilic and acidophilic bacterium
    • Authors: Jamil, F., Teh, A.-H., Schadich, E., Najimudin, N., Alam, M.
    • Year: 2014
    • Journal: Journal of Biochemistry
    • Citations: 8
  7. Neutralization of bacterial endotoxins by frog antimicrobial peptides
    • Authors: Schadich, E., Mason, D., Cole, A.L.
    • Year: 2013
    • Journal: Microbiology and Immunology
    • Citations: 12
  8. Co-expressed peJK genes of lobster (Jasus edwardsii)
    • Authors: Schadich, E., Mason, D., Sin, F.
    • Year: 2012
    • Journal: Australian Journal of Zoology
    • Citations: 1
  9. Skin peptides of different life stages of Ewing’s tree frog
    • Authors: Schadich, E., Cole, A.L.J., Squire, M., Mason, D.
    • Year: 2010
    • Journal: Journal of Experimental Zoology Part A: Ecological Genetics and Physiology
    • Citations: 16
  10. Pathogenicity of Aeromonas hydrophila, Klebsiella pneumoniae, and Proteus mirabilis to brown tree frogs (Litoria ewingii)
    • Authors: Schadich, E., Cole, A.L.J.
    • Year: 2010
    • Journal: Comparative Medicine
    • Citations: 28

 

 

Moein Masjedi | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Moein Masjedi | Pharmacology | Best Researcher Award

Moein Masjedi, DarooSazan Sorena Exir Pharmaceutical Company, Iran.

Moein Masjedi is a dedicated researcher in the field of pharmacology, recognized for his innovative contributions to drug development and therapeutic strategies. With a strong academic background and a commitment to advancing scientific knowledge, he has published numerous influential papers that address critical challenges in the field. Awarded the Best Researcher Award for his outstanding research impact, Moein continues to inspire peers and students through his passion for improving health outcomes and enhancing patient care.

Profile:

Education

Moein Masjedi earned his Doctor of Pharmacy degree from Shiraz University of Medical Sciences in Shiraz, Fars, Iran, where he completed his thesis on the drug utilization evaluation of captopril in two coronary care units at Namazi Hospital, achieving a GPA of 15.64 out of 20. He then pursued a Ph.D. in Pharmaceutics at the same institution, focusing on the nose-to-brain delivery of Sumatriptan using chitosan nanoparticles and nanostructured lipid carriers (NLCs), and graduated with a GPA of 17.83 out of 20.

 

Skills 

Moein Masjedi possesses a diverse skill set that enhances his effectiveness as a researcher and collaborator. He excels in strong and collaborative communication, fostering teamwork and idea exchange. His creativity in problem-solving and critical thinking enables him to tackle complex challenges in pharmacology. Demonstrating leadership qualities, he effectively manages projects while prioritizing time management to meet deadlines. Additionally, he is skilled in structural scientific writing and proofreading, ensuring clarity and precision in his research publications. Beyond academia, Moein has a passion for art interpretation and enjoys swimming and yoga, which contribute to his overall well-being and work-life balance.

Areas of Interest:

Moein Masjedi’s research interests focus on innovative drug delivery systems and formulation design. He is particularly passionate about nanoparticulate drug delivery and the optimization of formulations for pulmonary, ocular, topical, and transdermal applications. His work includes designing novel drug delivery systems targeting specific sites such as the pulmonary system, colon, brain, and hair follicles. He explores the use of nanovesicles, lipid, and polymeric nanoparticles for both therapeutic and cosmetic applications. Additionally, Moein is interested in D-optimal optimization of aesthetic formulations and the development of stimuli-responsive or smart polymers for drug delivery. He employs Design of Experiments (DoE) methodologies to optimize formulations and is also engaged in the innovative 3D printing of pharmaceutical dosage forms, aiming to advance the field of pharmaceutics.

Publication Top Notes

  1. Masjedi, M., Izadi, Y., Montahaei, T., Mohammadi, R., Helforoush, M. A., & Rohani Rad, K. (2024). An illustrated review on herbal medicine used for the treatment of female infertility. European Journal of Obstetrics and Gynecology and Reproductive Biology, 0(0).
  2. Dahri, M., Beheshtizadeh, N., Seyedpour, N., Nakhostin-Ansari, A., Aghajani, F., Seyedpour, S., Masjedi, M., Farjadian, F., Maleki, R., & Adibkia, K. (2023). Biomaterial-based delivery platforms for transdermal immunotherapy. Biomedicine & Pharmacotherapy, 165, 115048.
  3. Rezaie, F., Farshbaf, M., Dahri, M., Masjedi, M., Maleki, R., Amini, F., Wirth, J., Moharamzadeh, K., Weber, F. E., & Tayebi, L. (2023). 3D printing of dental prostheses: Current and emerging applications. Journal of Composites Science, 7(2), 80.
  4. Masjedi, M., Montahaei, T., Sharafi, Z., & Jalali, A. (2022). Pulmonary vaccine delivery: An emerging strategy for vaccination and immunotherapy. Journal of Drug Delivery Science and Technology, 103184.
  5. Masjedi, M., & Solhjoo, A. (2022). Does trigonelline help skin tone? Molecular docking studies of trigonelline on the human tyrosinase, formulation, optimization and characterization of an emulgel containing Trigonella foenum‐graecum L. fenugreek standardized hydroalcoholic extract. Journal of Cosmetic Dermatology.
  6. Masjedi, M., & Namazi, S. (2020). Drug utilization evaluation (DUE) of captopril in two coronary care units (CCU) of Namazi Hospital, Shiraz, Iran.
  7. Masjedi, M., & Montahaei, T. (2020). An illustrated review on nonionic surfactant vesicles (niosomes) as an approach in modern drug delivery: Fabrication, characterization, pharmaceutical, and cosmetic applications. Journal of Drug Delivery Science and Technology, 102234.
  8. Masjedi, M., Azadi, A., Heidari, R., & Mohammadi-Samani, S. (2020). Brain targeted delivery of sumatriptan succinate loaded chitosan nanoparticles: Preparation, in vitro characterization, and (neuro-) pharmacokinetic evaluations. Journal of Drug Delivery Science and Technology, 102179.
  9. Ziaei, A., Davoodian, P., Dadvand, H., Safa, O., Hassanipour, S., Omidi, M., Masjedi, M., Mahmoudikia, F., Rafiee, B., & Fathalipour, M. (2020). Evaluation of the efficacy and safety of melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials, 21(1), 1-3.
  10. Masjedi, M., Azadi, A., Heidari, R., & Mohammadi‐Samani, S. (2020). Nose‐to‐brain delivery of sumatriptan‐loaded nanostructured lipid carriers: Preparation, optimization, characterization, and pharmacokinetic evaluation. Journal of Pharmacy and Pharmacology, 72(10), 1341-1351.

Shailaja Jadhav | Pharmaceutics | Women Researcher Award

Posted on by ScienceFather

Mrs. Shailaja Jadhav | Pharmaceutics | Women Researcher Award

Assistant Professor at Gourishankar Institute of Pharmaceutical Education and Research Limb, Satara, India.

Mrs. Shailaja Vishal Jadhav is a dedicated researcher and academic in the field of pharmaceutical sciences, with a focus on advanced drug delivery systems and nanotechnology. Currently pursuing her Ph.D., she has demonstrated a strong commitment to research and education, holding an assistant professor position and contributing to her field through publications and presentations. Her work is recognized nationally, and she continues to push the boundaries of pharmaceutical research with her innovative approaches.

Profile:

Education

Mrs. Jadhav holds a Bachelor’s degree in Pharmacy (B. Pharm) and a Master’s degree in Pharmacy (M. Pharm) from Shivaji University, Kolhapur. She is currently pursuing her Ph.D. at the Government College of Pharmacy, Karad, under Shivaji University, where she has submitted her final thesis, awaiting her viva examination. Her solid academic foundation is reflected in her consistent academic performance, with notable scores during her undergraduate and postgraduate studies.

 

Professional Experiences 

Mrs. Jadhav brings a wealth of both academic and industrial experience to her career. She has accumulated over eight years of teaching experience, including five years as an Assistant Professor at the Gourishankar Institute of Pharmaceutical Education and Research in Satara. Additionally, she has undergone industrial training at Meditab Specialities Pvt. Ltd., where she gained practical exposure to pharmaceutical processes. This combination of academic instruction and hands-on experience in the industry has enriched her practical and theoretical knowledge in pharmaceutical sciences.

Research Interests

Mrs. Shailaja Vishal Jadhav’s research interests are primarily focused on Novel Drug Delivery Systems (NDDS), formulation and development, and nanotechnology. She is passionate about exploring innovative approaches to improve the efficacy and safety of drug delivery. Her Ph.D. research revolves around the extraction and quantification of bioactive compounds, specifically focusing on Supercritical CO2 Extraction and the pharmacological screening of Steroidal Saponins from natural sources. Additionally, her interest in nanotechnology aims at developing nanoscale drug delivery methods that can enhance targeted therapies and minimize side effects, making her work highly relevant in the fields of pharmaceutical and biomedical sciences.

 

Research skills 

Her research expertise lies in Novel Drug Delivery Systems (NDDS), formulation and development, and nanotechnology. She is proficient in using sophisticated laboratory instruments such as HPLC, UV/Visible spectrophotometer, and particle size analyzers, which are critical for her research. Her Ph.D. research focuses on supercritical CO2 extraction and steroidal saponins, reflecting her skills in both cutting-edge extraction techniques and pharmacological screening. Her ability to combine advanced scientific methods with real-world applications makes her a strong asset to the research community.

 

Award And Recoginition 

Mrs. Jadhav has received multiple awards and recognitions throughout her academic journey. Most notably, she was awarded the prestigious Chhatrapati Shahu Maharaj National Research Fellowship (CSMNRF-2020) by the Government of Maharashtra for her Ph.D. research. She secured the 3rd rank in the Shivaji University Ph.D. Entrance Examination and achieved 2nd place in an international symposium poster presentation. Her research work has also been published in a high-impact journal, underscoring the quality and significance of her contributions to pharmaceutical science.

 

Conclusion

Mrs. Shailaja Vishal Jadhav’s academic qualifications, research achievements, and diverse professional experience make her a strong candidate for the Research for Women Researcher Award. Her current Ph.D. pursuit, national fellowship, and publication record demonstrate her potential for significant contributions to her field. Finalizing her Ph.D. and expanding her research outputs could further elevate her candidacy.

 

Publication Top Notes
  • Title: Natural Polymer-Based Formulation and Characterization of Matrix-Controlled Release Tablet of Losartan Potassium Employing Sintering Technique
    Authors: Dr. A. S. Kulkarni, S. V. Jadhav*, Dr. N. H. Aloorkar
    Year: 2019
    Citation: European Journal of Biomedical and Pharmaceutical Sciences, Volume 6, Issue 10, 312-322
    📅💊🌿
  • Title: Phytoconstituents Based Nanomedicines for the Management of Diabetes: A Review
    Authors: Shailaja Jadhav*, Dr. Adhikarao Yadav
    Year: 2023
    Citation: Pharmaceutical Nanotechnology, Bentham Science Publisher, Volume 11, Issue 3, 217-237. DOI: 10.2174/2211738511666230118095936
    🌱🧪🔬
  • Title: Supercritical CO2 Extraction, Quantification, and Pharmacological Screening of Steroidal Saponins from Fruits of Momordica Charantia L
    Authors: Shailaja Jadhav*, Adhikrao Yadav
    Year: 2023
    Citation: International Journal of Pharmaceutical Quality Assurance, Volume 14, Issue 3, July-September, 563-572
    🍈💧⚗️
  • Title: Molecular Docking Studies of Antidiabetic Biomolecule Charantin Isolated from Fruits of Momordica Charantia L
    Authors: Shailaja Jadhav*, Adhikrao Yadav
    Year: 2024
    Citation: Advances in Bioresearch, Volume 15, Issue 2, March 2024, 182-189. DOI: 10.15515/abr.0976-4585.15.2.182189
    🧬🔍🧫
  • Title: Enhanced Antidiabetic Performance Through Optimized Charantin-Loaded Nanostructured Lipid Carriers: Formulation and In Vivo Studies in Diabetic Mice
    Authors: Shailaja Jadhav*, Dr. Adhikarao Yadav, Sameer Nadaf
    Year: 2024
    Citation: Journal of Drug Delivery Science and Technology. DOI: 10.1016/j.jddst.2024.106208
    🧑‍🔬🐭💉

Soha Ismai | Pharmacology, Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Posted on by ScienceFather

Assist Prof Dr. Soha Ismai | Pharmacology, Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Assistant Professor, EDA, Egypt

With a solid foundation in pharmacy, including a Bachelor’s, Master’s, and PhD from Cairo University, and a position as Associate Professor, this individual demonstrates exceptional expertise. Their diverse professional experience spans quality control, management, and academic roles, showcasing their leadership and practical knowledge in the pharmaceutical field. Their prolific research output includes numerous publications on advanced drug delivery systems and nanotechnology, reflecting significant contributions to pharmaceutical sciences. Active participation in various training courses, workshops, and international conferences highlights their commitment to continuous professional development. Additionally, their multilingual skills enhance their ability to collaborate in diverse settings. Overall, their comprehensive background in education, research, and professional development, combined with their active engagement in the scientific community, makes them a highly suitable candidate for the Best Researcher Award.

Education

The candidate has a robust educational background that serves as the foundation of their expertise in the field of pharmaceutical sciences. They earned a Bachelor of Pharmacy degree from Cairo University in 1996, graduating with honors, which set the stage for their academic and professional journey. Their pursuit of advanced knowledge led them to complete a Master’s degree in Pharmaceutics in 2007 and later a PhD in 2011, both from the same esteemed institution. This rigorous academic training has equipped them with in-depth knowledge of pharmaceutics, drug formulation, and pharmaceutical analysis. In 2019, they further solidified their academic credentials by attaining the position of Associate Professor, demonstrating their commitment to education, research, and mentorship. Their continuous academic progression reflects a strong commitment to excellence and a desire to contribute significantly to the pharmaceutical sciences, positioning them as a thought leader in their field and a prime candidate for the Best Researcher Award.

Profesional Experience

The candidate has an extensive professional background in the pharmaceutical sector, beginning their career as a QC analyst for raw materials at NODCAR from 1996 to 1999. They then transitioned to academia as a teaching assistant at the Faculty of Pharmacy, October University, in 1999. Between 2000 and 2012, they worked as a QC analyst specializing in physical properties before moving into management roles, including quality manager and deputy lab manager. From 2016 to 2021, they served as a technical manager, demonstrating their expertise in overseeing laboratory operations and maintaining quality standards. Their role expanded further as they joined several committees, contributing to updating pharmaceutical guidelines and developing the Egyptian pharmacopeia. In 2021, they became the lab manager of the physicochemical lab at the Egyptian Drug Authority (EDA), where they continue to lead and innovate in quality control and research.

Research Skill

The candidate possesses exceptional research skills, demonstrated through a prolific publication record in high-impact journals and extensive experience in developing innovative pharmaceutical formulations. They have expertise in designing and conducting complex experimental studies, including the use of advanced methodologies like Box–Behnken design for optimization and in vivo evaluations. Their research work spans various domains, including nanotechnology, ocular drug delivery, and gastroretentive systems, showcasing versatility and a strong ability to adapt to emerging scientific trends. Additionally, their role in supervising master’s and PhD theses highlights their leadership in guiding future researchers. The candidate is also well-versed in utilizing statistical analysis tools and quality-by-design approaches, which are critical for ensuring the rigor and reliability of research findings. Their ability to translate research into practical applications, coupled with active participation in committees that shape pharmaceutical guidelines, underscores a profound impact on both academic and industry standards in the pharmaceutical sciences.

Awards And Recoginition

The individual has received multiple accolades throughout their career, reflecting their outstanding contributions to the field of pharmaceutical sciences. Their expertise in pharmaceutics and dedication to research have been recognized by esteemed institutions and professional bodies. Notably, they have been honored for their innovative work in drug delivery systems and quality management, which have had a significant impact on the pharmaceutical industry. They have been a valuable member of committees responsible for updating pharmaceutical guidelines and establishing national standards, further highlighting their influence and leadership in the field. Additionally, their research publications in renowned international journals have been widely cited, earning them recognition among peers as a leading researcher. Their participation in prestigious conferences and workshops, both as a presenter and a participant, underscores their commitment to continuous learning and sharing knowledge. These recognitions affirm their position as a distinguished professional dedicated to advancing pharmaceutical science and improving healthcare outcomes.

Conclution

The individual’s blend of academic excellence, practical experience, prolific research output, and continuous professional growth makes them a highly suitable candidate for the Best Researcher Award. Their achievements reflect their dedication to advancing pharmaceutical science and their impact on the field.

Publication Top Notes

  1. Enhanced wound healing activity of naturally derived Lagenaria siceraria seed oil binary nanoethosomal gel: formulation, characterization, in vitro/in vivo efficiency
    • Authors: Nagham H. Kamal, Fatema R. Saber, Abeer Salama, Dalia M. N. Abouhussein, Soha Ismail, Hala M. El-Hefnawy, Meselhy R. Meselhy
    • Year: 2024
    • Citation: Kamal NH, Saber FR, Salama A, Abouhussein DMN, Ismail S, El-Hefnawy HM, Meselhy MR. Enhanced wound healing activity of naturally derived Lagenaria siceraria seed oil binary nanoethosomal gel: formulation, characterization, in vitro/in vivo efficiency. Future Journal of Pharmaceutical Sciences. 2024 Aug 19. doi:10.1186/s43094-024-00678-2.
  2. Mucoadhesive Chitosan Composite Sponge as a Carrier for β-Sitosterol Cubosomes for Thermal Burn Treatment
    • Authors: Abeer Khattab, Soha Ismail, Areeg M. Abd-Elrazek
    • Year: 2024
    • Citation: Khattab A, Ismail S, Abd-Elrazek AM. Mucoadhesive Chitosan Composite Sponge as a Carrier for β-Sitosterol Cubosomes for Thermal Burn Treatment. AAPS PharmSciTech. 2024 Jun 27. doi:10.1208/s12249-024-02852-4.
  3. Optimization of topical curcumin spanlastics for melanoma treatment
    • Authors: Soha Ismail, Doaa Garhy, Howida K. Ibrahim
    • Year: 2023
    • Citation: Ismail S, Garhy D, Ibrahim HK. Optimization of topical curcumin spanlastics for melanoma treatment. Pharmaceutical Development and Technology. 2023 May 28. doi:10.1080/10837450.2023.2204926.
  4. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box–Behnken design and in vivo evaluation
    • Authors: Marwa H. Shukr, Soha Ismail, Ghada G. El-Hossary, Amany H. El-Shazly
    • Year: 2022
    • Citation: Shukr MH, Ismail S, El-Hossary GG, El-Shazly AH. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box–Behnken design and in vivo evaluation. Journal of Liposome Research. 2022 Oct 2. doi:10.1080/08982104.2022.2025828.
  5. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI
    • Authors: Marwa Farrag Abd El-Aziz, Soha Ismail, Mina Ibrahim Tadros, Mohamed Ahmed Elnabarawi
    • Year: 2020
    • Citation: Abd El-Aziz MF, Ismail S, Tadros MI, Elnabarawi MA. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI. Pharmaceutical Development and Technology. 2020 May 27. doi:10.1080/10837450.2020.1720235.
  6. Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity
    • Authors: Marwa H. Shukr, Soha Ismail, Samya Mahmoud Ahmed
    • Year: 2019
    • Citation: Shukr MH, Ismail S, Ahmed SM. Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity. Journal of Drug Delivery Science and Technology. 2019 Feb. doi:10.1016/j.jddst.2018.12.001.
  7. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy
    • Authors: Dalia S. Shaker, Soha Ismail, Selwan Hamed, Eman M. El-Shishtawy
    • Year: 2018
    • Citation: Shaker DS, Ismail S, Hamed S, El-Shishtawy EM. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy. Journal of Drug Delivery Science and Technology. 2018 Dec. doi:10.1016/j.jddst.2018.09

 

Bashige Chiribagula Valentin | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Bashige Chiribagula Valentin | Pharmaceutical Science | Best Researcher Award

Professor of UNILU, Congo.

Dr. Bashige Chiribagula Valentin is a prominent academic and researcher specializing in ethnopharmacology, medicinal chemistry, and quality control. Currently a professor at the University of Lubumbashi, he has held roles including department head, research specialist in pharmacognosy, and educator in pharmacology. His research focuses on the ethnobotanical, phytochemical, and pharmacological properties of medicinal plants, with significant contributions to the development of traditional medicine-based therapies, such as antimalarial and antimicrobial agents. Dr. Chiribagula has led various projects aimed at enhancing the quality and efficacy of herbal remedies and has published extensively in reputed journals. His work includes studies on plant-based treatments for malaria, diabetes, and wound healing, reflecting his commitment to integrating traditional knowledge with modern scientific approaches. His leadership in the academic and scientific community, coupled with his impactful research, underscores his candidacy for the Best Researcher Award.

Profile
Education

Dr. Bashige Chiribagula Valentin’s educational background is extensive and well-rounded. He earned his Doctorate in Pharmaceutical Sciences from the University of Lubumbashi (UNILU) and the Université de Mons (UMONS) in 2021, specializing in Pharmacognosy with a focus on ethnopharmacology. Prior to this, he obtained a Diplôme d’Études Approfondies in Pharmacognosy from UNILU in 2016. His foundational education includes a Diplôme de Pharmacie d’Industrie et Analyse de Médicaments from UNILU, completed in 2012, and a Diplôme d’Études Générales en Sciences Pharmaceutiques from the University of Kinshasa (UNIKIN) in 2006. His academic journey demonstrates a strong commitment to advancing knowledge in pharmaceutical sciences, particularly in the areas of pharmacognosy and ethnopharmacology.

Professional Experience

Dr. Bashige Chiribagula Valentin has an extensive and diverse professional background in the field of pharmacognosy and ethnopharmacology. He has served as a Professor at the University of Lubumbashi since 2022, where he also holds positions as President of juries and Secretary of the Department of Pharmacology. His career at the university began as an Assistant in 2013, progressing to a Chief of Works and Specialist in Pharmacognosy. In addition to his academic roles, Dr. Chiribagula has been actively involved in the pharmaceutical industry as a Quality Control Manager at PROMED Lubumbashi. His research focuses on ethnopharmacology, medicinal chemistry, and quality control of medicinal plants, contributing significantly to the development of traditional medicine projects. Dr. Chiribagula’s career also includes roles in secondary education and civil society, showcasing his dedication to both education and community service.

Research Interest

Dr. Bashige Chiribagula Valentin’s research focuses on the ethnopharmacological and medicinal properties of plants, particularly in the context of traditional medicine. His work spans the study of plant-based remedies for various diseases, including malaria and diabetes, with a strong emphasis on the pharmacognosy of medicinal plants. Dr. Chiribagula’s research integrates ethnobotanical surveys, phytochemical analysis, and pharmacological testing to explore and validate the therapeutic potential of natural substances. His projects include the development of medicinal plants for wound healing, anti-malarial, anti-ulcer, and antibacterial applications. Additionally, he investigates the nutritional and medicinal benefits of indigenous fungi, fruits, and vegetables. His research aims to bridge traditional knowledge with modern scientific validation, contributing to the development of effective, natural therapeutic agents and enhancing the quality of life in the Democratic Republic of Congo.

Research Skills

Dr. Bashige Chiribagula Valentin demonstrates a robust set of research skills essential for advancing his field of study. His expertise spans ethnopharmacology, medicinal chemistry, and quality control, with a strong emphasis on the pharmacognostic and phytochemical evaluation of medicinal plants. Dr. Chiribagula excels in employing various analytical techniques, including chromatography (TLC, Flash, HPLC), spectral analysis (MS), and microbiological assays (antimicrobial testing, antioxidant assays). His proficiency in using statistical software such as SPSS and GraphPad supports his rigorous data analysis. Additionally, he has a solid background in experimental design and execution, demonstrated by his work on traditional medicine and natural product research. His ability to integrate traditional knowledge with scientific methodologies underscores his contributions to the development of novel therapeutic agents and quality control measures in pharmaceuticals. Dr. Chiribagula’s comprehensive approach and methodological skills are integral to his research successes.

Awards and Recognition

Dr. Bashige Chiribagula Valentin has garnered significant recognition for his contributions to pharmacognosy and ethnopharmacology. He was honored as the “Major de Promotion” in 2012 and achieved notable accolades in 2019, securing first place at the MT180 regional AUF competition and second place at the national MT180 competition. His scholarly excellence is highlighted by his award-winning research on ethnobotanical studies and medicinal plants, which has been recognized in several prestigious journals. Dr. Chiribagula’s impactful work in the development of medicinal plant-based treatments, including those for malaria and wound healing, has further solidified his reputation in the scientific community. These awards underscore his dedication to advancing knowledge in pharmaceutical sciences and his commitment to improving public health through innovative research.

Conclusion

Bashige Chiribagula Valentin is a strong candidate for the Research for Best Researcher Award due to his substantial contributions to ethnopharmacology, his significant publications, and his active role in academia and the pharmaceutical industry. His expertise in traditional medicine and his impactful research on medicinal plants, coupled with his notable awards and professional experience, underline his qualifications for the award.

Publications Top Notes

  • Ethnomedical Knowledge of Plants Used in Nonconventional Medicine for Wound Healing in Lubumbashi, Haut‐Katanga Province, DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2024
  • Ethnomedicinal Knowledge of Plants Used in Nonconventional Medicine in the Management of Diabetes Mellitus in Kinshasa (Democratic Republic of the Congo)
    • Authors: Bashige Chiribagula Valentin
    • Year: 2023
  • Ethnobotanical study of plants used by traditional healers in Lubumbashi (Democratic Republic of Congo) in the management of typhoid fever
    • Authors: Bashige Chiribagula Valentin
    • Year: 2022
  • Activité antioxydante de 53 plantes réputées antimalariques en République Démocratique du Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • In vitro antioxidant activity and in vivo aphrodisiac activity in male Cavia porcellus of Albizia adianthifolia (Schum.) W. Wight and Pericopsis angolensis (Baker) Meeuwen
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Knowledge, attitudes and practices among the population, towards COVID-19 in the Lubumbashi city (DR Congo): An online cross-sectional survey
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Mineral elements analysis and total flavonoids content in the fresh leaves from two varieties of Hibiscus sabdariffa L. consumed as vegetable in Lubumbashi (DR Congo)
    • Authors: Bashige Chiribagula Valentin
    • Year: 2021
  • Antimicrobial, antioxidant activities and toxicity on Cavia porcellus of Dialium angolense Welw. Ex Oliv, a traditional medicinal plant from Bagira in Eastern of DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020
  • Ethnobotanical study of medicinal plants used in the treatment of sexual dysfunctions in traditional medicine in Kampemba-Lubumbashi, DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020
  • Antiplasmodial, antioxidant and toxicological study of leaves extracts of Dalbergia katangensis Lecheneaud (Fabaceae) from Eastern DR Congo
    • Authors: Bashige Chiribagula Valentin
    • Year: 2020

 

Justine Benevent | Pharmaceutical Science | Best Scholar Award

Posted on by ScienceFather

Dr. Justine Benevent | Pharmaceutical Science | Best Scholar Award

MCU-PH at CHU Toulouse, INSERM CERPOP, France

Based on the provided information, Justine Benevent appears to be a strong candidate for the Best Scholar Award. Here is a detailed assessment of her suitability, structured by various criteria:

Education

Justine Benevent’s educational background is distinguished by a series of advanced degrees in pharmacology and related fields. She holds a Diplôme d’état de Docteur en Pharmacie from Bordeaux, providing a comprehensive foundation in pharmacy. She further specialized with a DESC de Pharmacologie médicale from Bordeaux, focusing on medical pharmacology. Her academic journey continued with a Thèse d’Université de Pharmacologie in Toulouse, where she engaged in in-depth research. She also earned a Diplôme Universitaire de pédagogie en Santé from Toulouse, enhancing her skills in health education. Additionally, she completed the DES Pharmacie hospitalière from Bordeaux, highlighting her expertise in hospital pharmacy. These qualifications reflect her extensive training and dedication to the field of pharmacology, underpinning her expertise and contributions to research and clinical practice.

Research Contributions

Justine Benevent has made significant research contributions in pharmacology, with a focus on medications, reproduction, pregnancy, and breastfeeding. She has a solid publication record with 33 papers, including 6 as the first author, and a notable h-index of 10, indicating her research impact and recognition in the academic community.

Geographic Impact

Her research has a wide geographic impact, involving collaborations with international institutions such as PharmaSafe at the University of Oslo, Norway. Her work with the European Consortium IMI ConcePTION highlights her ability to engage in research that transcends national boundaries, addressing health issues relevant to diverse populations.

Collaborative Efforts

Justine Benevent is actively involved in several collaborative research projects and networks. She is a partner of the European Consortium IMI ConcePTION, a member of the national network REGARDs, and participates in various working groups, including those focused on mental health and reproductive risks of drugs. These collaborations demonstrate her commitment to multi-disciplinary and international research efforts.

Applied Research

Her research is highly applied, focusing on real-world health issues such as the effects of medications during pregnancy and breastfeeding. Her role in the project “Maison des Femmes” at CHU de Toulouse, aimed at improving healthcare for women, underscores her dedication to applying research findings to enhance community health and well-being.

Specific Projects and Publications

Justine Benevent has led and contributed to numerous impactful projects. Her work within the “Santé périnatale, pédiatrique et des adolescents” team at CERPOP addresses critical aspects of perinatal and pediatric health. She has also been involved in leading two projects within the IMI ConcePTION consortium, further highlighting her leadership in significant research initiatives.

Environmental Health

While her primary focus is on pharmacology and reproductive health, her work indirectly impacts environmental health by addressing the safe use of medications during critical periods such as pregnancy and breastfeeding. This contributes to overall community health by ensuring safer pharmaceutical practices.

Vector Control

There is no direct mention of research in vector control in her profile. However, her extensive work in pharmacology and drug safety may intersect with public health strategies that could include elements of vector control indirectly.

Waste Management and Water Quality

Justine Benevent’s profile does not indicate direct involvement in waste management and water quality research. Her expertise lies primarily in pharmacology and clinical research methodology.

Parasitology and Infectious Diseases

Although parasitology and infectious diseases are not explicitly mentioned, her pharmacological research, especially in the context of reproductive health, could contribute to understanding and managing infections that affect pregnant women and infants.

Awards and Recognition

Justine Benevent’s academic and research achievements have been recognized through various positions and memberships, such as her role as Treasurer of the CNPM (Collège National de Pharmacologie Médicale) and her involvement in the French Society of Pharmacology and Therapeutics (SFPT). Her significant publication record and citation count further attest to her recognition in the field.

Conclusion

Justine Benevent is a highly accomplished scholar with a strong background in pharmacology, evidenced by her extensive research contributions, collaborative efforts, and applied research impact. Her work addresses crucial health issues related to medications and reproductive health, making her a deserving candidate for the Best Scholar Award. Her leadership in various national and international research projects and her dedication to improving community health through applied research are particularly commendable.

Publications Top Notes

  1. Teaching pharmacovigilance to French medical students during the COVID-19 pandemic: Interest of distance learning clinical reasoning sessions
    • Authors: F. Montastruc, F. Muscari, I. Tack, G. Durrieu, A. Sommet
    • Year: 2024
  2. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: A systematic review and meta-analysis
    • Authors: L. Saint-Lary, J. Benevent, C. Damase-Michel, V. Leroy, A. Sommet
    • Year: 2023
    • Citations: 2
  3. Drug monitoring in pregnant women: about the Regards network | Surveillance des médicaments chez les femmes enceintes : à propos du réseau Regards
    • Authors: I. Lacroix, M. Araujo, A. Caillet, L. Delteil, C. Damase-Michel
    • Year: 2023
    • Citations: 1
  4. Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database
    • Authors: J. Benevent, M. Araujo, S. Karki, S. Tebeka, C. Damase-Michel
    • Year: 2023
    • Citations: 2
  5. Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age?
    • Authors: M. Balon, S. Tessier, C. Damase-Michel, J. Benevent, I. Lacroix
    • Year: 2023
    • Citations: 5
  6. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database
    • Authors: J. Benevent, M. Araujo, A.-B. Beau, I. Lacroix, C. Damase-Michel
    • Year: 2023
    • Citations: 3
  7. Interactions between antiseizure medications and contraception: A study about the knowledge of patients and their specialist physicians
    • Authors: A. Gosset, M. Denuelle, L. Valton, B.énévent, F. Tremollières
    • Year: 2022
    • Citations: 5
  8. Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study
    • Authors: J. Benevent, C. Hurault-Delarue, M. Araujo, I. Lacroix, C. Damase-Michel
    • Year: 2022
  9. What changes in prescription patterns of antiemetic medications in pregnant women in France?
    • Authors: C. Hurault-Delarue, M. Araujo, C. Vabre, C. Damase-Michel, I. Lacroix
    • Year: 2021
    • Citations: 4
  10. Maternal Medication Use and Childhood Cancer in Offspring-Systematic Review and Considerations for Researchers
    • Authors: S. Hjorth, C.H. Hemmingsen, J. Benevent, M. Hargreave, H. Nordeng
    • Year: 2021
    • Citations: 2

 

 

Taigang Liang | Drug Design | Best Researcher Award

Posted on by ScienceFather

Prof. Taigang Liang | Drug Design | Best Researcher Award

Professor at School of Pharmacy/Shanxi Medical University, China.

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Professional Profiles:

Education

Prof. Tai Gang Liang, a distinguished scientist at Shanxi Medical University’s School of Pharmacy, has a robust educational background in pharmaceutical sciences. He earned his Doctor of Philosophy (PhD) in 2011, Master of Science (MS) in 2003, and Bachelor of Science (BS) in 2000, all from Shanxi Medical University. His extensive expertise spans drug synthesis, drug action mechanisms, computer-aided drug design, and the industrialization of traditional Chinese medicine (TCM). Prof. Liang’s research is recognized for its contributions to both the development of novel drug compounds and innovative drug design methodologies. His academic journey reflects a deep commitment to advancing pharmaceutical sciences and addressing global health challenges through cutting-edge research.

Professional Experience

Prof. Tai Gang Liang is a distinguished scientist at the School of Pharmacy, Shanxi Medical University, with extensive expertise in drug synthesis, drug action mechanisms, and computer-aided drug design. His research also focuses on the industrialization of traditional Chinese medicine (TCM). Over his career, Prof. Liang has received several prestigious awards, including being named a Shanxi Province Outstanding Young Scholar and a member of the Shanxi Province “131 Leading Talent Engineering.” He also earned the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition. His work has made significant contributions to advancing pharmaceutical sciences and TCM research, reflecting his dedication to innovation and excellence in the field.

 Research Interest

Prof. Tai Gang Liang’s research interests encompass a broad spectrum within pharmaceutical sciences. His primary focus includes drug synthesis and drug action mechanisms, where he aims to develop novel therapeutic agents and understand their biological effects. He is also deeply involved in computer-aided drug design, utilizing computational tools to optimize drug development processes. Additionally, Prof. Liang investigates the industrialization of traditional Chinese medicine (TCM), striving to integrate traditional practices with modern scientific techniques to enhance the efficacy and application of TCM therapies. His research aims to bridge the gap between traditional and modern medicinal approaches, advancing both fields through innovative solutions and interdisciplinary collaboration.

Award and Honors

Prof. Tai Gang Liang has received several notable awards and honors in recognition of his contributions to the field of pharmaceutical sciences. He was named a Shanxi Province Outstanding Young Scholar, highlighting his exceptional achievements and potential in his research domain. He is also a member of the Shanxi Province “131 Leading Talent Engineering”, an accolade given to influential professionals in the province. Additionally, Prof. Liang was awarded the Silver Prize at the 12th “Challenge Cup” China College Entrepreneurship Plan Competition, reflecting his innovative approach and entrepreneurial spirit in scientific endeavors. These accolades underscore his dedication and significant impact in drug development and traditional Chinese medicine. 🏆🌟

 Research Skills

Prof. Tai Gang Liang excels in drug synthesis, focusing on developing novel pharmaceutical compounds. His research spans drug action mechanisms, where he explores how drugs interact with biological systems to produce therapeutic effects. Liang is skilled in computer-aided drug design, using computational tools to optimize drug candidates efficiently. He also integrates Traditional Chinese Medicine (TCM) with modern scientific methods to advance drug development and industrialization. His expertise extends to biological evaluation techniques, sustainable synthesis, and analytical methods, ensuring comprehensive assessments of drug efficacy and safety. Prof. Liang’s innovative approaches contribute significantly to enhancing drug discovery and development processes. 🧪🔬💻

Publications
  1. Green synthesis of selenium nanoparticles with extract of hawthorn fruit induced HepG2 cells apoptosis
    • Authors: D Cui, T Liang, L Sun, L Meng, C Yang, L Wang, T Liang, Q Li
    • Year: 2018
    • Citations: 112
  2. Comparison of the Phenolic Content and Antioxidant Activities of Apocynum venetum L. (Luo-Bu-Ma) and Two of Its Alternative Species
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 107
  3. Selenium nanoparticles fabricated in laminarin polysaccharides solutions exert their cytotoxicities in HepG2 cells by inhibiting autophagy and promoting apoptosis
    • Authors: D Cui, J Ma, T Liang, L Sun, L Meng, T Liang, Q Li
    • Year: 2019
    • Citations: 93
  4. Synthesis, characterization and antitumor properties of selenium nanoparticles coupling with ferulic acid
    • Authors: D Cui, C Yan, J Miao, X Zhang, J Chen, L Sun, L Meng, T Liang, Q Li
    • Year: 2018
    • Citations: 78
  5. Chemopreventive Effects of Peucedanum praeruptorum DUNN and Its Major Constituents on SGC7901 Gastric Cancer Cells
    • Authors: T Liang, W Yue, Q Li
    • Year: 2010
    • Citations: 51
  6. Farrerol Directly Targets GSK‐3β to Activate Nrf2‐ARE Pathway and Protect EA.hy926 Cells against Oxidative Stress‐Induced Injuries
    • Authors: C Yan, X Zhang, J Miao, H Yuan, E Liu, T Liang, Q Li
    • Year: 2020
    • Citations: 37
  7. Apoptosis induced by farrerol in human gastric cancer SGC-7901 cells through the mitochondrial-mediated pathway
    • Authors: E Liu, T Liang, X Wang, S Ban, L Han, Q Li
    • Year: 2015
    • Citations: 35
  8. Diorganotin (IV) complexes with 4-nitro-N-phthaloyl-glycine: Synthesis, characterization, antitumor activity and DNA-binding studies
    • Authors: C Yan, J Zhang, T Liang, Q Li
    • Year: 2015
    • Citations: 35
  9. Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs
    • Authors: X Qin, X Hou, M Zhang, T Liang, J Zhi, L Han, Q Li
    • Year: 2014
    • Citations: 31
  10. Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest
    • Authors: E Liu, J Li, S Shi, X Wang, T Liang, B Wu, Q Li
    • Year: 2016
    • Citations: 26